C9orf72 and amyotrophic lateral sclerosis: An ongoing double bind, placebo-controlled, study (NCT04931862) is expected to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of WVE-004 in patients with C9orf72-associated ALS or FTD.